Microbiome specialist Enterobiotix Ltd. has raised £19 million (US$25.7 million) to fund phase IIb development of its lead program EBX-102-02 in the treatment of irritable bowel syndrome with constipation (IBS-C).
Biopharma and med-tech companies raising money in public or private financings, including: Citius, Fathom, Lucid, Plaquetec, Sagimet, Sanofi, Sonoma, Squaremind.
Nervonik Inc. raised $52.5 million in a series B financing round for its peripheral nerve stimulation (PNS) system designed to treat patients with chronic pain and other neurological conditions. The funds will be used to support the continued development Nervonik's PNS system, including enhancements to the system’s sensing capabilities, as well as preparations for commercialization.
The funding momentum that was building at the end of 2025 was maintained in the first quarter (Q1) of 2026, with a rebound in venture capital (VC) investment in U.K. biotech. Overall investment in the sector during Q1 was £552 million (US$748 million), of which £516 million was in VC.
Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.
Biopharma and med-tech companies raising money in public or private financings, including: Maze, Milestone, Nektar, Outlook, Preveceutical, Tarsier, Tuhura.
Biopharma and med-tech companies raising money in public or private financings, including: Alesi Surgical, Deep Blue Medical, Flagship, Kailera, Pulmatrix, Ray, Serif, Spruce, Trevi.
RSS
